478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study
| Autor: | Palazzo, A., Toss, A., Graffeo, R., Fontana, A., Lambertini, M., Pantaleo, F., Perachino, M., Nerone, M., Bianco, N., Vici, P., de Marchis, L., Staropoli, N., Rinaldi, L., Lai, A., Spinelli, G.P., Di Monte, E., Giotta, F., Gennari, A., Cortesi, L., Bria, E. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S382-S382 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|